New Delhi (Anish Yande): Natco Pharma shares are up by 4% on Monday's trading session. The shares of the pharma company received emergency use approval for Baricitinib tablets from the Indian drug regulator.
Shares of Natco Pharma opened at Rs 929 on Monday. Natco Pharma shares rose to an intraday high of Rs 934 per share on Monday from the previous close of Rs 896.35.
Natco Pharma gets emergency use approval for Baricitinib tablets:
Natco Pharma has received emergency use approval for Baricitinib tablets from the Central Drugs Standard Control Organisation. The CDSCO is a drug regulator in India.
In an exchange filing, the pharma firm has received Emergency Use approval for Baricitinib tablets, in strengths of 1mg, 2mg, and 4mg.
The drug is used along with Remdesivir for the treatment of COVID-19 positive patients.
Natco had requested a compulsory license for the drug for emergency use. The pharma firm cited the public health emergency across India for emergency use. Natco Pharma is preparing to launch the Baricitinib tablets in India this week. The product would be made available to Covid-19 patients in India.
Baricitinib is an oral tablet medication that is sold through a prescription with the brand name Olumiant. The US Food and Drug Administration had issued emergency use approval for Baricitinib along with Remdesivir for the treatment of Covid-19. The medicine is for patients diagnosed with Covid-19 admitted in hospitals that require supplemental oxygen and mechanical ventilation.
Natco Pharma seeks approval of Molnupiravir:
Previously, Natco Pharma had requested CDSCO for approval of Phase-III clinical trial of Molnupiravir Capsules. Molnupiravir is developed by Ridgeback Biotherapeutics and American pharma major Merck. The drug is used for the treatment of COVID-19 positive patients.
Natco is expecting emergency approval of Molnupiravir based on 'compassionate use' for Covid-19 patients.
According to Natco, pre-clinical data has indicated that the medicine has broad anti-influenza activity and prevents the replication of SARS-CoV-2. The pharma firm has stated that Molnupiravir showed results in 5 days of therapy and has an additional advantage of being an oral therapy.
Image Credit: Google